“Thank you for helping me to get the I-140 approval.”
General Field: Cancer Immunotherapy
Position at the Time of Case Filing: Senior Scientist
Country of Origin: India
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: March 24th, 2022
Processing Time: 3 days (Premium Processing Requested)
“Cancer, in general, has a severe impact on not only patients and their families but also economic resources and opportunities in the US due to morbidity, financial loss, reduced quality of life, and premature death. As a foremost expert in cancer immunotherapy, [the client] specializes in the research and development of novel therapies for all kinds of cancers, making her contributions a boon to the American healthcare sector. I lend her my full support in her continued endeavors.”
This statement supports the work of one of our clients from India. She had come to NAILG seeking help with her EB1-A (Alien of Extraordinary Ability) petition. At the time of filing, she held a Ph.D. in immunology and was employed as a senior scientist in cancer immunotherapy. It was evident to our team that she was an extraordinary individual and one of the few leading cells therapy experts in the area. Additionally, she held a consistent and notable record of success and influence in this area of study.
Our client was especially well-known for her work on developing personalized chimeric antigen receptor T (CAR T) cell-based immunotherapies for patients diagnosed with mutations in epidermal growth factor receptors in glioblastoma multiforme. Given that she had spent years investigating these issues, she had come to be regarded as an authority in the field. The field had also recognized her authority by inviting her to review and evaluate the work of her peers no fewer than 2 times.
At the same time, her work has resulted in 9 peer-reviewed scientific articles, 1 patent, and 2 patent applications. And these publications have been cited by researchers in at least 49 countries some 554 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of cancer immunotherapy.
This was the reason that her work in the area found many supporters such as the 4 experts who wrote recommendations in our client’s favor. These letters were of immense help in the adjudication process since the USCIS demands clear proof of extraordinary ability from petitioners in this category. One of these experts had the following to say about the continuation of her work in the United States:
“To curb the devastating effects that cancer has on patients and the economy, the discovery of novel therapeutics for the disease is necessary. [The client] has dedicated her career to investigating this topic as it relates to glioblastoma, Acute Myelogenous Leukemia, pancreatic cancer, and several other forms of the disease. For progress in this area to continue at its present pace, she must be allowed to continue her research unabated.”
Finally, when we received her EB1-A approval in the record time of just 3 days, we could not contain our happiness. We are also grateful for her continuing trust in our firm, and for retaining us to file her I-485 application and successfully receiving her green card 4 months after we filed her case. We cordially thank her for her support and wish her the best in her future endeavors.
North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).
Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend
With more than 16,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.
We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours
With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.
Vast Majority of Clients Came to Us Because of Referrals
For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 3,500 in 2019.
Approval Notices: https://www.wegreened.com/eb1_niw_approvals
Success Stories: https://www.wegreened.com/blog/
Free evaluation email: email@example.com
Tel: 888.666.0969 (Toll Free)
To see more clients’ testimonials and approvals, please refer to: